Vacc-4x , Presented at AIDS Vaccine 2011 Bangkok

[sam66]

     From Binor website:

    Vacc-4x presented at AIDS Vaccine 2011 in Bangkok

(BANGKOK, Sep 12, 2011) Bionor Pharma presented Vacc-4x on "Global HIV Vaccine Enterprise" press conference at AIDS Vaccine 2011 in Bangkok

Bionor Pharma was the only company with therapeutic HIV-vaccine having a presentation at Global HIV Vaccine Enterprise (GHVE) press conference, where the aim was to present promising HIV projects.

GHVE is a unique alliance of organizations that has the convening power to bring together an inclusive global alliance of top researchers, funders, advocacy groups, and stakeholders to catalyze fresh thinking, set new directions and advance global cooperation to develop an HIV vaccine.

Professor Jan van Lunzen, Medical Director Infectious Diseases at Hamburg-Eppendorf University, who is one of the investigators in the Vacc-4x phase IIB study, presented Vacc-4x on behalf of Bionor.

Link to a video of the press conference


    http://app2.capitalreach.com/esp1204/servlet/tc?c=10188&cn=aidsvac&s=20457&dp=player.jsp&e=16016&mediaType=slideVideo

[Tim Horn]

All I can say, really, is that many of van Lunzen's comments are based on secondary measures and a post-hoc analysis of the data. The primary goal of the study was to look at the time ARV treatment needed to be resumed in both the Vacc-4x group and the placebo group. Unfortunately, there was no statistically significant difference here -- across the board, patients treated with Vacc-4x were no more likely to stay off therapy longer than those treated with placebo (there may not have been enough time off treatment in the main study to ferret out key differences).

http://www.aidsmeds.com/articles/hiv_vacc4x_bionor_1667_21134.shtml

A lot of the encouraging stuff discussed by van Lunzen is pretty much limited to a subset of individuals who were able to stay off treatment, beginning at week 28 and through to week 52.

There's still some interesting stuff here, to be sure. The question now, I guess, is figuring out how to maximize the results, not only to keep people off ARVs, but to harness the immune system's ability to keep viral loads undetectable.

[elf]

They need to combine 3 ''modesty effective'' vaccines to get one that is >90% effective.